Bad, Bad Baxter

Shares of Baxter International (NYSE: BAX  ) were down 6% to $29 after the latest in a series of earnings warnings this year that have shaken investor confidence.

This morning, the medical products company said fourth-quarter earnings from continuing operations would come in between $0.62 and $0.65 per share, resulting in full-year earnings from continuing operations in the range of $1.52 to $1.55 per share. Back in October, the company had forecasted fourth-quarter earnings of $0.75 to $0.85 per share and reiterated full-year earnings of $1.65 to $1.75 per share.

Full-year 2003 sales growth will still be in the 8%-10% range due to positive growth trends for its recombinant factor VIII and medication delivery products. Baxter also expects gross margins to rise sequentially from the third quarter. However, earnings will be reduced by an "unfavorable geographic mix" and a lower-than-expected gain from the sale of the company's investment in Acambis (Nasdaq: ACAM  ) , a U.K.-based vaccine developer. A gain of $0.03 per share from that sale is included in the company's forecast.

At the beginning of 2003, Baxter had forecast full-year earnings of $2.22 to $2.29 per share. But slow sales and intense competition for its blood plasma products caused the company to lower its estimates in March. As a result, the stock fell from near its current level to under $20 per share. Then in July, the company lowered its outlook again to between $1.65 and $1.75 per share, taking a $0.33-per-share restructuring charge.

The stock had since rebounded on hopes for Advate, Baxter's new hemophilia treatment. However, a weaker-than-expected third-quarter report put an end to that, and today's warning does not help.

Baxter's frequent earnings warnings put a serious question mark on the credibility of its management's forecasts. You almost have to wonder why they even bother to give them in the first place. Expect continued pressure on Baxter's stock until the company's management can gain some level of consistency.

Discuss busted forecasts on the Baxter discussion board -- only at Jeff Hwang can be reached at

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 500693, ~/Articles/ArticleHandler.aspx, 10/21/2016 1:29:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,110.27 -52.08 -0.29%
S&P 500 2,138.33 -3.01 -0.14%
NASD 5,251.51 9.68 0.18%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 1:14 PM
BAX $47.88 Down -0.31 -0.64%
Baxter CAPS Rating: ****